CUBT — Curative Biotechnology Income Statement
0.000.00%
Last trade - 00:00
HealthcareSpeculativeMicro Cap
- $14.62m
- $15.47m
2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 0 | 0 | 0 |
Cost of Revenue | |||
Gross Profit | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Unusual Expense / Income | |||
Total Operating Expenses | -0.223 | 4.64 | 5.16 |
Operating Profit | 0.223 | -4.64 | -5.16 |
Total Net Non Operating Interest Income / Expense | |||
Net Income Before Taxes | 0.207 | -4.67 | -5.34 |
Net Income After Taxes | 0.207 | -4.67 | -5.34 |
Net Income Before Extraordinary Items | |||
Net Income | 0.207 | -4.67 | -5.34 |
Adjustments to Net Income | |||
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | 0.207 | -4.67 | -18.8 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -0 | -0.008 | -0.033 |